Clinical Trials Browser

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Recurrence

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Clinical Trials

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

LIGHT

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Magic-C002

Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma

PLATINUM

DIAMOND

Adjuvant vs Surgery Only in Early-stage Recurrent NPC

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Metastatic Nasopharyngeal Carcinoma

A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma

GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

GEMSTONE

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

NPC-Nivo

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

GNT Induction Treatment in Locally Advanced NPC

Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Toripalimab and Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma.

Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma